CMA
RPRX icon

Cedar Mountain Advisors’s Royalty Pharma RPRX Stock Holding History

Cedar Mountain Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.98K Hold
178
– – ﹤0.01% 498
2026
Q1 		$8.54K Buy
+178
New +$7.8K ﹤0.01% 506

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cedar Mountain Advisors's RPRX Position: Q2 2026 in Review

Cedar Mountain Advisors held its Royalty Pharma (RPRX) position steady in Q2 2026 at 178 shares worth $9.98K. The position accounts for ﹤0.01% of the portfolio, ranked #498.

Cedar Mountain Advisors first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cedar Mountain Advisors held 178 shares of Royalty Pharma worth $9.98K as of Q2 2026.
  • Cedar Mountain Advisors left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #498 holding.
  • Cedar Mountain Advisors first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.